Generics substitution in Finland: a pharmacy customer perspective Posted 19/06/2020

Generics offer less expensive alternatives to brand-name drugs. However, they must be accepted by patients to increase uptake and reduce healthcare cost. Finland adopted generics substitution in 2003. Then, in 2009, this was supplemented with a reference price system. A recent survey [1] has shown that the price of medicine is key for Finnish pharmacy customers.
In 2018, 1,043 Finnish pharmacy customers over the age of 18, were surveyed to explore reasons for allowing and refusing generics substitution. The results showed that, these customers, almost 50% had both refused and allowed generics substitution in the past, just over 40% had always allowed substitution and 6% had always refused substitution. The survey also revealed the reasons behind customer decisions. Just over 75% of customers allowed substitution to reduce medical bills. Almost 60% of customers had allowed substitution because their prescribed medicine or the medicine they had used before, was unavailable. On the other hand, customers refused generics substitution when the price difference between interchangeable medicines was insignificant (over 60%) and when they were satisfied with the medicine used before (just over 60%). Overall, the main factors influencing customers’ choice of an interchangeable prescription medicine were priced (over 80%), familiarity (almost 40%) and availability (just over 30%). Customers who had allowed substitution chose the medicine based on price. Customers who had only refused substitution appreciated familiarity with the medicine more than its price. The survey highlighted that it is important to make price information available. However, customers do regard several factors when making choices about interchangeable medicines.
Related articles Reference pricing and generics in Finland Factors important for generics substitution in Finland
Reference Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing. Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.
Policies to lower prices of generics in Austria and Finland
1. Nokelainen H, Lämsä E, Ahonen R. Reasons for allowing and refusing generic substitution and factors determining the choice of an interchangeable prescription medicine: a survey among pharmacy customers in Finland. BMC Health Serv Res. 2020;20(1):82.
Comments (0)
Generics News Research General
- Adherence improves long-term prognosis and medi...Generics/Research | Posted 19/02/2021
- Anti-competitive strategic patenting by pharmac...Generics/Research | Posted 12/02/2021
- Biocon and Lupin launch generic tacrolimus caps...Generics/News | Posted 05/02/2021
- New generics company to offer low-cost versions...Generics/General | Posted 29/01/2021
Biosimilars News Research General
- Improving stakeholder understanding about biosi...Biosimilars/Research | Posted 19/02/2021
- Canada approves infliximab biosimilar Remsima SCBiosimilars/News | Posted 19/02/2021
- Innovent starts phase II trial for ipilimumab c...Biosimilars/News | Posted 19/02/2021
- EMA recommends approval of adalimumab biosimila...Biosimilars/News | Posted 12/02/2021